Get the Stockscreener App
35.53
5.34%
1.80
Moderna Inc stock is traded at $35.53, with a volume of 21.01M.
It is up +5.34% in the last 24 hours and down -1.00% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$33.73
Open:
$33.89
24h Volume:
21.01M
Relative Volume:
1.95
Market Cap:
$13.67B
Revenue:
$5.06B
Net Income/Loss:
$-2.22B
P/E Ratio:
-6.1048
EPS:
-5.82
Net Cash Flow:
$-3.96B
1W Performance:
+7.70%
1M Performance:
-1.00%
6M Performance:
-59.00%
1Y Performance:
-59.44%
1-Day Range:
$33.18
$35.97
1-Week Range:
$32.04
$36.98
52-Week Range:
$29.25
$170.47
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
35.53 | 13.67B | 5.06B | -2.22B | -3.96B | -5.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Handelsbanken Fonder AB Has $6.53 Million Stake in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
UBS Group Issues Pessimistic Forecast for Moderna (NASDAQ:MRNA) Stock Price - MarketBeat
Why Moderna Inc. (MRNA) Surged On Friday? - MSN
CIBC Asset Management Inc Lowers Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna Stock: The Future Unveiled! Innovative Tech to Drive Explosive Growth! - Reporteros del Sur -
Market plunges after new Coronavirus reported in Wuhan but Pfizer and Moderna stock soars - Daily Mail
Moderna (NASDAQ:MRNA) Trading 8.8% HigherWhat's Next? - MarketBeat
Investors in Moderna, Inc. Should Contact Levi & Korsinsky Before October 8, 2024 to Discuss Your RightsMRNA - ACCESS Newswire
Moderna and Other Vaccine Stocks Climb After Coronavirus News From China - MSN
Chinese researchers find bat virus enters human cells via same pathway as COVID -February 21, 2025 at 05:56 pm EST - Marketscreener.com
Moderna and Other Vaccine Stocks Climb Amid Concerns About Coronavirus Study in China - Yahoo Finance
Moderna Sees Unusually High Options Volume (NASDAQ:MRNA) - MarketBeat
Moderna (NASDAQ:MRNA) Trading Up 8.8%Time to Buy? - MarketBeat
Moderna (NASDAQ:MRNA) Trading Down 7.9% Following Analyst Downgrade - MarketBeat
Moderna, Novavax rise as new bat coronavirus identified in China - MSN
Moderna stock rises amid new virus concerns By Investing.com - Investing.com Australia
Analyst calls of the week: Rivian, Block, Moderna, Bumble... - Proactive financial news
Moderna, Inc. SEC 10-K Report - TradingView
Rx Rundown: Moderna, Sanofi, GSK and more - MM+M Online
Meitav Investment House Ltd. Sells 184,043 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Should You Buy, Hold or Sell Moderna Stock Post Q4 Earnings Release? - MSN
Moderna, Inc. to Host Earnings Call - ACCESS Newswire
MRNA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Moderna, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Baillie Gifford & Co. Lowers Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Levi & Korsinsky Notifies Moderna, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineMRNA - ACCESS Newswire
Moderna stock plunges nearly 17% after company lowers 2025 sales forecast by $1 billion - MSN
Will Moderna Stock Drop to $25? 1 Wall Street Analyst Thinks So. - Nasdaq
Moderna (MRNA) Expected to Announce Earnings on Thursday - MarketBeat
Intrinsic Value Partners LLC Lowers Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna's (MRNA) "Sector Perform" Rating Reiterated at Royal Bank of Canada - MarketBeat
Wall Street Thinks This Beaten-Down Growth Stock Can Soar 85% in 2025. Should You Buy It Now? - MSN
EMA Urged Pfizer And Moderna To Boost Production Volume Of COVID Vax - BW Healthcare World
UBS Adjusts Moderna Price Target to $78 From $96, Maintains Buy Rating -February 19, 2025 at 10:21 am EST - Marketscreener.com
Why Moderna (MRNA) Went Up on Tuesday? - Yahoo Finance
Moderna: A Generational Opportunity for Investors in 2025 - MarketBeat
Flagship Pioneering Appoints Paul Owen as CEO-Partner and CEO of YourBio Health - Quantisnow
Moderna (NASDAQ:MRNA) Stock Rating Lowered by Barclays - MarketBeat
Moderna price target lowered to $78 from $96 at UBS - TipRanks
Trump’s Hammer Hits FDA, Moderna Falls Further and Patent Cliffs Loom - BioSpace
Barclays Downgrades Moderna (WBAG:MRNA) - Nasdaq
Rep. Julie Johnson Sells Moderna, Inc. (NASDAQ:MRNA) Shares - MarketBeat
Louisiana State Employees Retirement System Sells 30,100 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Q4 2024 Earnings Call Transcript - MSN
Barclays Downgrades Moderna (MRNA) - MSN
Barclays Downgrades Moderna (BIT:1MRNA) - Nasdaq
Moderna Downgraded by Barclays as Policy Risks and Weak Revenue Weigh on Outlook - GuruFocus.com
Why Moderna (MRNA) Stock Is Up Today By Stock Story - Investing.com Canada
Moderna's Stock Increases by 11.8% Despite Market ChallengesNews and Statistics - IndexBox, Inc.
MRNA: Moderna Stock Rises on Financial Results Despite Downgrade - GuruFocus.com
Moderna rises 8% even as Barclays downgrades - Seeking Alpha
Moderna shares move higher as investors look beyond Q4 losses - Proactive Investors UK
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):